FDA clears PhotoMedex' laser for leukoderma:
This article was originally published in Clinica
Executive Summary
PhotoMedex has received US FDA clearance to expand the use of its XTRAC laser system to the treatment of leukoderma, the loss of skin pigmentation often a result of injury to the skin caused by trauma, surgery, laser therapy and burns. The device stimulates melanocyte migration and proliferation by the release of cytokines and inflammatory mediators in the skin, which lead to re-pigmentation, says the Radnor, Pennsylvania firm. The laser is already cleared for treating psoriasis, vitiligo and eczema.